Advanced

The burden of rheumatoid arthritis and access to treatment: determinants of access

Lundqvist, J; Kastäng, F; Kobelt, Gisela LU and Jönsson, B (2008) In European Journal of Health Economics 8(Suppl. 2). p.87-93
Abstract
As pan of the study "The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment", this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified... (More)
As pan of the study "The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment", this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
rheumatoid arthritis, health technology assessment, treatment access
in
European Journal of Health Economics
volume
8
issue
Suppl. 2
pages
87 - 93
publisher
Springer
external identifiers
  • wos:000253955400006
  • scopus:38449089887
ISSN
1618-7601
DOI
10.1007/s10198-007-0090-1
language
English
LU publication?
yes
id
6c203c2f-a21f-4669-b2d7-c9ea9f244889 (old id 1186271)
date added to LUP
2008-09-03 14:15:50
date last changed
2017-10-22 03:37:20
@article{6c203c2f-a21f-4669-b2d7-c9ea9f244889,
  abstract     = {As pan of the study "The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment", this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED).},
  author       = {Lundqvist, J and Kastäng, F and Kobelt, Gisela and Jönsson, B},
  issn         = {1618-7601},
  keyword      = {rheumatoid arthritis,health technology assessment,treatment access},
  language     = {eng},
  number       = {Suppl. 2},
  pages        = {87--93},
  publisher    = {Springer},
  series       = {European Journal of Health Economics},
  title        = {The burden of rheumatoid arthritis and access to treatment: determinants of access},
  url          = {http://dx.doi.org/10.1007/s10198-007-0090-1},
  volume       = {8},
  year         = {2008},
}